🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Solid Tumor

Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 NK Cell Therapy for Malignant Solid Brain Tumors NCT07552233NA4 sites📍 Beijing📍 Qinhuangdao📍 Zhengzhou Peking University Third Hospital · Tests: Autologous NK cells A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. NCT04116541Phase 213 sites📍 Angers📍 Bordeaux📍 Caen Centre Leon Berard · Tests: HDM201, Ribociclib, Cabozantinib, Alectinib, Regorafenib AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors NCT05372640Phase 17 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing Collection and Storage of Tissue and Blood Samples From Patients With Cancer NCT02474160n/a140 sites📍 Birmingham📍 Fort Smith📍 Arroyo Grande National Cancer Institute LAO · Tests: Cytology Specimen Collection Procedure Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors NCT07469982Phase 11 site📍 Shanghai Shouyao Holdings (Beijing) Co. LTD · Tests: SY-9453 Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors NCT04684459EARLY Phase 11 site📍 Chengdu Sichuan University · Tests: Dual-targeting HER2 and PD-L1 CAR-T cells A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 NCT06410092Phase 13 sites📍 Beijing📍 Chongqing📍 Chengdu Sound Biopharmaceuticals Ltd. · Tests: FTL001 A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 NCT06240728Phase 18 sites📍 Baltimore📍 Boston📍 The Bronx NextPoint Therapeutics, Inc. · Tests: NPX887 Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT05631964Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06960395Phase 14 sites📍 Scottsdale📍 Houston📍 Wollongong Vir Biotechnology, Inc. · Tests: VIR-5525, Pembrolizumab Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer NCT07664579n/a1 site📍 Duarte City of Hope Medical Center · Tests: Non-Interventional Study Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors NCT07415863Phase 1, Phase 21 site📍 Beijing CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6043 PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors NCT07510828Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy, Cytokine support A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy